drugset / Trial / NCT05647512
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Timeline
- Start
- 2023-01-18
- Primary completion
- 2024-12-01
- Completion
- 2025-12-30
Outcome
Outcome not reported
Stopped (Business): “According to sponsor strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | LM-305 | Unknown | — | Intravenous |